文献速递妇科生殖医学

下一代测序揭示子宫腺肌症发病机制

Adenomyosis pathogenesis: insights from next-generation sequencing.
PubMed 文献 · Hum Reprod Update · 2021-01-01

本综述综合下一代测序研究,探讨子宫腺肌症的细胞起源与分子机制。靶向深度测序发现腺肌症及邻近基底层内膜腺上皮均存在复发性KRAS突变,支持基底层内膜内陷学说,且KRAS突变可能部分解释细胞存活延长与孕激素抵抗。

要点

  • KRAS突变见于宫腔内膜与近端腺肌症样本,支持内陷学说。
  • KRAS等突变限于子宫内膜型上皮细胞,也见于子宫内膜异位症。
  • KRAS激活突变刺激细胞存活与增殖通路,与孕激素抵抗相关。

核心结论

  • 腺肌症可能起源于携带KRAS驱动突变的基底层内膜上皮细胞,通过内陷进入肌层。

研究设计与样本

  • 综述综合截至2020年PubMed收录的人类与动物研究,涵盖NGS、全外显子/基因组测序、RNA测序、靶向深度测序等。

主要发现

  • 靶向深度测序显示腺肌症及邻近基底层内膜腺上皮均存在复发性KRAS突变。
  • 子宫内膜、邻近腺肌症及共存子宫内膜异位症的上皮细胞共享相同KRAS突变。
  • 腺肌症与子宫内膜异位症均为寡克隆组织,源于携带特定驱动突变的内膜细胞群。
  • 子宫肌瘤平滑肌细胞中的驱动突变在腺肌症中缺失。
  • 腺肌症与子宫内膜异位症均报道有雌激素生物合成增加、雌二醇代谢减少、ESR2驱动的炎症过程及孕激素受体表达降低所致孕激素抵抗。

临床怎么用

  • KRAS突变状态可能有助于理解腺肌症的孕激素抵抗机制。
  • 腺肌症与子宫内膜异位症共享分子特征,提示二者可能采用相似的靶向治疗思路。
  • 对于有妊娠等破坏内膜-肌层交界事件史的患者的反复月经,需警惕基底层内膜内陷风险。

局限性

  • 本文为综述,未报告原始研究的具体样本量、效应值或置信区间。
  • KRAS突变在腺肌症发病中的确切因果作用仍需进一步功能研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adenomyosis, characterized by the presence of islands of endometrial tissue surrounded by hypertrophic smooth muscle cells within the myometrium, is one of the most challenging uterine disorders in terms of diagnosis and management. Adenomyosis presents with pelvic pain, excessive uterine bleeding, anemia and infertility. The relative contributions of abnormal endometrial tissue and myometrial smooth muscle cells to the development and growth of adenomyosis are not well understood. Moreover, there is continuing debate on the origins of adenomyosis; two competing theories describe the invagination of basal endometrium into the myometrium or the metaplastic differentiation of remnant endometrial stem/progenitor cells within the myometrium. OBJECTIVE AND RATIONALE: A recent series of next-generation sequencing (NGS) studies have provided the best scientific evidence thus far regarding the cellular origins of adenomyosis and the contributions of new signaling pathways to its pathogenesis, survival, and growth. These seminal studies on endometrium, adenomyosis and endometriosis demonstrate or support the following key points. (i) Mutations of KRAS map to both intracavitary endometrial tissue and proximally located adenomyotic samples, supporting the invagination theory of pathogenesis. Driver mutations found in smooth muscle cells of uterine fibroids are absent in adenomyosis. (ii) KRAS and other less frequent mutations are limited to endometrial-type epithelial cells. They are also observed in endometriosis, indicating that the disease process in adenomyosis is similar to that in endometriosis and distinct from that of uterine fibroids. (iii) Activating mutations of KRAS stimulate specific pathways to increase cell survival and proliferation and are associated with progesterone resistance in adenomyosis. Together, these findings suggest that distinct cell populations in eutopic endometrial tissue play key roles in the etiology of adenomyosis. Dependence on ovarian steroids and ovulatory cycles for disease severity is a unique feature of adenomyosis. In this context, common patterns of aberrant gene expression have been reported both in adenomyosis and endometriosis. These include pathways that favor increased estrogen biosynthesis, decreased estradiol metabolism, a unique estrogen receptor beta (ESR2)-driven inflammatory process, and progesterone resistance due to decreased progesterone receptor expression. Since adenomyosis exhibits a uniquely estrogen-driven inflammatory process and progesterone resistance, we discuss the interactions between these molecular characteristics and signaling pathways induced by the newly discovered KRAS mutations. SEARCH METHODS: We conducted a comprehensive search using PubMed for human and animal studies published until 2020 in the following areas: adenomyosis, endometriosis, endometrium, NGS, whole-exome sequencing, whole-genome sequencing, RNA sequencing, targeted deep sequencing, epigenetics, driver mutation, KRAS, progesterone resistance, estrogen action and steroid production. OUTCOMES: Targeted deep sequencing analyses of epithelial cells in adenomyosis and adjacent basalis endometrial glands demonstrated recurring KRAS mutations in both cell types. This finding suggests that adenomyosis originates from basalis endometrium. Epithelial cells of the endometrium, adjacent adenomyosis and co-occurring endometriosis also share identical KRAS mutations. These findings suggest both adenomyosis and endometriosis are oligoclonal tissues that arise from endometrial cell populations carrying a specific driver mutation that most commonly affects the KRAS gene. WIDER IMPLICATIONS: Adenomyosis usually follows an event such as pregnancy that has disrupted the integrity of the endometrial-myometrial junction followed by repetitious menstrual episodes that increase the likelihood of the entrapment of the basalis endometrium within the myometrium. Glandular epithelial cells carrying KRAS mutations and located within the deep crypts of basalis endometrium may become entrapped and invade myometrial tissue to give rise to adenomyosis. Evidence suggests that KRAS mutations may be responsible, in part, for previously observed phenomena such as prolonged cell survival and progesterone resistance in adenomyosis.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Bulun SE, Yildiz S, Adli M, et al. Adenomyosis pathogenesis: insights from next-generation sequencing. Hum Reprod Update. 2021. PMID: 34131719. doi:10.1093/humupd/dmab017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。